CoChat

Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation

Open access

The DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index; 15 of the 67 sources its claims cite were checked for support.

Abstract

One of the benefits of Digital PCR (dPCR) is the potential for unparalleled precision enabling smaller fold change measurements. An example of an assessment that could benefit from such improved precision is the measurement of tumour-associated copy number variation (CNV) in the cell free DNA (cfDNA) fraction of patient blood plasma. To investigate the potential precision of dPCR and compare it with the established technique of quantitative PCR (qPCR), we used breast cancer cell lines to investigate HER2 gene amplification and modelled a range of different CNVs. We showed that, with equal experimental replication, dPCR could measure a smaller CNV than qPCR. As dPCR precision is directly dependent upon both the number of replicate measurements and the template concentration, we also developed a method to assist the design of dPCR experiments for measuring CNV. Using an existing model (based on Poisson and binomial distributions) to derive an expression for the variance inherent in dPCR, we produced a power calculation to define the experimental size required to reliably detect a given fold change at a given template concentration. This work will facilitate any future translation of dPCR to key diagnostic applications, such as cancer diagnostics and analysis of cfDNA.

Overview

CoChat Summary

TL;DR

This study directly compares microfluidic digital PCR (dPCR) with conventional quantitative PCR (qPCR) for measuring HER2 copy number variation using breast cancer cell line DNA and spiked DNA models. It reports that dPCR can detect smaller CNVs than qPCR at equal replication and provides a Poisson/binomial variance model with power calculations to design dPCR experiments based on template concentration.

Key findings

  • dPCR and qPCR gave similar HER2:RNase P ratios for normal female gDNA (1.03 vs 1.00; P = 0.39), MCF-7 (0.44 by both; P = 0.71), and T-47D (2.00 vs 1.96; P = 0.52), but SK-BR-3 was significantly lower by dPCR (7.15) than qPCR (9.43; P = 0.00005).
  • In an in vitro gene-amplification model at low copy number (2.1 ng/μl; λr ≈ 0.2), dPCR detected a ratio of ≥1.17 with eight panels (P < 0.0003), whereas qPCR detected ratios of ≥1.27 with eight wells (P < 0.0005); a 1.12 ratio was not significantly different from normal female gDNA by dPCR with eight panels, and ratios ≤1.22 were not significantly different by qPCR.
  • Power calculations predicted that with 95% power and λr = 0.2, a 1.2-fold change was detectable with five 770-chamber panels per assay, ratios of 1.1 and below required >15 panels, and the smallest CNV measurable with eight panels was approximately 1.15.
  • For qPCR, power curves indicated ratios greater than 1.25 could be measured with 95% power and eight replicate wells, while an excess of 20 qPCR wells would be needed to measure ratios of 1.17 or fewer.

Methods

  • Genomic DNA from three breast cancer cell lines with different HER2 status (SK-BR-3, T-47D, MCF-7) and pooled normal female gDNA was analyzed with HER2 and RNase P assays by qPCR and microfluidic dPCR on 48.770 arrays.
  • An in vitro CNV model was created by spiking T-47D gDNA into normal female gDNA to generate theoretical HER2:RNase P ratios between 1.00 and 2.00 at low copy number.
  • dPCR quantification used Poisson estimation of molecules per chamber (λ = −ln(1 − H/C)); qPCR used standard curves. Statistical comparisons used ANOVA and two-tailed Student’s t-tests, and power calculations were performed in R based on a derived variance model for the log ratio.

Limitations

  • Stated: the proof-of-principle experiments used high-quality DNA template to model cfDNA; translation will require consideration of template integrity, PCR-assay efficiency, and matrix effects.
  • Stated: dPCR may not accurately quantify concatameric HER2 amplifications such as those in SK-BR-3, and pre-amplification to separate linked copies requires careful validation because of potential bias.
  • Evident from the text: the findings are tied to one microfluidic dPCR platform (Fluidigm 48.770), specific HER2/RNase P assays, and a one-tailed power model focused on HER2 amplification, so generalizability to other platforms, assays, or deletion/two-tailed CNV settings is not established here.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/nar/gks203

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Comparison of HER2:RNase P ratio in breast cancer cell line genomic DNA using digital and quantitative real-time PCR. (a) Software-generated heat map showing a single panel in a 48.770 dPCR array that contains 770 chambers with positive (white) and negative (black) amplification signals. One representative dPCR panel is shown for each gDNA sample and assay with the number of positive chambers shown in the top right corner of the panel. Positive and negative chambers were used to calculate the number of molecules per panel and the HER2:RNase P ratio for the gDNA sample. The NTC panels for both assays had no positive chambers. (b) qPCR (n = 8 wells) and dPCR (n = 4 panels) gave similar HER2:RNase P ratios for all BC gDNA except the SK-BR-3 gDNA that was significantly higher by qPCR compared with dPCR (asterisk). Data is presented on a log scale and error bars represent 95% CIs.
Figure 1. Comparison of HER2:RNase P ratio in breast cancer cell line genomic DNA using digital and quantitative real-time PCR. (a) Software-generated heat map showing a single panel in a 48.770 dPCR array that contains 770 chambers with positive (white) and negative (black) amplification signals. One representative dPCR panel is shown for each gDNA sample and assay with the number of positive chambers shown in the top right corner of the panel. Positive and negative chambers were used to calculate the number of molecules per panel and the HER2:RNase P ratio for the gDNA sample. The NTC panels for both assays had no positive chambers. (b) qPCR (n = 8 wells) and dPCR (n = 4 panels) gave similar HER2:RNase P ratios for all BC gDNA except the SK-BR-3 gDNA that was significantly higher by qPCR compared with dPCR (asterisk). Data is presented on a log scale and error bars represent 95% CIs.CC BY-NC · PubMed Central
Figure 2. Determination of CNV detection of digital and quantitative real-time PCR. Quantitation of HER2:RNase P ratios using (a) dPCR and (b) qPCR generated from the in vitro gene-amplification model. The x-axis shows the expected HER2:RNase P ratio and the y-axis shows the observed HER2:RNase P ratios with the 95% CI. (a) For dPCR, four panels for each assay were analyzed for ratios > 1.5 (daggered symbol) and eight panels for each assay for ratios <1.5. In all cases, λr was approximately 0.2. The error bars represent the 95% CIs. (b) For qPCR, eight reactions were performed for each assay and all ratios. The error bars represent the 95% CIs calculated from the standard error of the mean and associated T-value with 95% confidence and seven degrees-of-freedom. Key: black triangle: normal female gDNA, black diamond: significantly different from normal female gDNA (P < 0.05), gray diamond: not significantly different from normal female gDNA (P > 0.05). Solid line of linear correlation is shown for those ratios that were significantly different from normal female gDNA. Dashed line is the extrapolation of the linear correlation showing intersection with HER2:RNase P ratio of 1.0. R2 and equations are given for the linear correlation.
Figure 2. Determination of CNV detection of digital and quantitative real-time PCR. Quantitation of HER2:RNase P ratios using (a) dPCR and (b) qPCR generated from the in vitro gene-amplification model. The x-axis shows the expected HER2:RNase P ratio and the y-axis shows the observed HER2:RNase P ratios with the 95% CI. (a) For dPCR, four panels for each assay were analyzed for ratios > 1.5 (daggered symbol) and eight panels for each assay for ratios <1.5. In all cases, λr was approximately 0.2. The error bars represent the 95% CIs. (b) For qPCR, eight reactions were performed for each assay and all ratios. The error bars represent the 95% CIs calculated from the standard error of the mean and associated T-value with 95% confidence and seven degrees-of-freedom. Key: black triangle: normal female gDNA, black diamond: significantly different from normal female gDNA (P < 0.05), gray diamond: not significantly different from normal female gDNA (P > 0.05). Solid line of linear correlation is shown for those ratios that were significantly different from normal female gDNA. Dashed line is the extrapolation of the linear correlation showing intersection with HER2:RNase P ratio of 1.0. R2 and equations are given for the linear correlation.CC BY-NC · PubMed Central
Figure 3. Determination of the number of dPCR panels needed to measure HER2:RNase P ratios. (a) Power curve to determine the number of panels required to detect different ratios of λt to λr, where λt > λr with 95% power at a confidence level of 95% and λr = 0.2. The two horizontal lines show a single-panel and eight-panel experiment where the intersections with the power curve indicates the lowest detectable CNV. The vertical line shows the smallest CNV detectable is approximately 1.15 when λr = 0.2 and the number of panels is 8. (b) The relevant number of dPCR panels (1–8) were selected and the HER2:RNase P ratio and associated 95% CIs were calculated. The graphs for the different ratios are slightly staggered to allow identification of the 95% CI error bars for each ratio. Ratios that are statistically different from the normal female gDNA are shown for ratios of 1.27 (gray asterisk) and 1.17 (black asterisk).
Figure 3. Determination of the number of dPCR panels needed to measure HER2:RNase P ratios. (a) Power curve to determine the number of panels required to detect different ratios of λt to λr, where λt > λr with 95% power at a confidence level of 95% and λr = 0.2. The two horizontal lines show a single-panel and eight-panel experiment where the intersections with the power curve indicates the lowest detectable CNV. The vertical line shows the smallest CNV detectable is approximately 1.15 when λr = 0.2 and the number of panels is 8. (b) The relevant number of dPCR panels (1–8) were selected and the HER2:RNase P ratio and associated 95% CIs were calculated. The graphs for the different ratios are slightly staggered to allow identification of the 95% CI error bars for each ratio. Ratios that are statistically different from the normal female gDNA are shown for ratios of 1.27 (gray asterisk) and 1.17 (black asterisk).CC BY-NC · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 16 Not checked · 62 Own results and interpretations

43 more claims

Create a free account to see all 92 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 31

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Cited by

See all 453

Metadata

Authors
Whale, A. S., Huggett, J. F., Cowen, S., Speirs, V., Shaw, J., Ellison, S., Foy, C. A., & Scott, D. J.
Affiliations
University of Leeds (GB)
Corresponding author
Huggett, Jim F.
Venue
Nucleic Acids Research
Published
2012-02-28
Volume
40
Issue
11
Pages
e82-e82
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2096206246
Cited by
453
References
53
Citations by year
2026: 33 · 2025: 32 · 2024: 20 · 2023: 36 · 2022: 29 · 2021: 36 · 2020: 33 · 2019: 34 · 2018: 24 · 2017: 32 · 2016: 48 · 2015: 31 · 2014: 30 · 2013: 27 · 2012: 6
FWCI
12.07
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by)
  • Leicester Research Archive (University of Leicester) (submittedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Government of the United Kingdom
  • Cancer Research UK (13462)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Molecular Biology Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
Keywords
digital PCR, copy number variation, real-time PCR, measurement precision, cell-free DNA, breast cancer cell lines, HER2 amplification, power analysis, template concentration, cancer diagnosis
MeSH terms
DNA, Neoplasm, Female, Gene Amplification, Humans, Polymerase Chain Reaction, Gene Dosage, Genes, erbB-2, Cell Line, Tumor, Microfluidic Analytical Techniques, DNA Copy Number Variations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.